CSL slashes 15% of workforce and offshoots vaccine division
Australia’s largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that…
-
FDA approves Papzimeos as first therapy for HPV-caused airway disease
The US Food and Drug Administration (FDA) has approved the first treatment for recurrent respiratory papillomatosis (RRP), a rare respiratory…
-
Trump targets bolstering of US emergency drug reserve
US President Donald Trump has ordered the bolstering of the country’s Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with important drugs,…
-
UK pharmacist says Eli Lilly’s Mounjaro price hike a “shock”
Eli Lilly will increase the UK list price of its blockbuster drug Mounjaro (tirzepatide) amid pressure from US President Donald…
-
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein-coupled receptors…
-
Basilea secures rights to Venatorx’s antibiotic for complicated UTIs
Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being developed for the treatment of complicated…
-
Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs
Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal challenge…
-
Insmed wins FDA approval for future blockbuster Brinsupri
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1)…
-
Podcast: US tariff news and Q2 earnings influence pharma trends
After months of negotiations, the EU and US reached an agreement to levy a 15% tariff on EU imports, which…